Role of stem cell transplant and maintenance therapy in plasma cell disorders.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Hematology. American Society of Hematology. Education Program

• Publication date

  2016-12-02

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/ASHEDUCATION-2016.1.504PMID 27913522PMCID PMC6142442
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lenalidomide (LEN) maintenance (MNTC) after high-dose melphalan and autologous stem cell transplant (ASCT) in multiple myeloma (MM): A meta-analysis (MA) of overall survival (OS).

  2016cited by this paper
• Allogeneic stem cell transplantation for multiple myeloma: is there a future?

  2016cited by this paper
• First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction.

  2016cited by this paper
• The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?

  2016cited by this paper
• Single versus tandem high‐dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long‐term results from the phase III GMMG‐HD2 trial

  2016influential reference
• Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.

  2016cited by this paper
• The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.

  2016cited by this paper
• What is new in diagnosis and management of light chain amyloidosis?

  2016cited by this paper
• Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.

  2016cited by this paper
• Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial).

  2016cited by this paper
• Myeloma: management of the newly diagnosed high-risk patient.

  2016cited by this paper
• American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip

  2015cited by this paper
• Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long-Term Follow-up of the HOVON-65/GMMG-HD4 Trial

  2015cited by this paper
• Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.

  2015cited by this paper
• American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multip

  2015cited by this paper
• Results from two phase III studies of bortezomib (BTZ) consolidation vs observation (OBS) post-transplant in patients (pts) with newly diagnosed multiple myeloma (NDMM).

  2015cited by this paper
• Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

  2015cited by this paper
• Management of relapsed multiple myeloma after autologous stem cell transplant.

  2015influential reference
• Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM): Keynote-023

  2015cited by this paper
• Oral Doxycycline Improves Outcomes of Stage III AL Amyloidosis - a Matched Case Control Study

  2015cited by this paper
• Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).

  2015cited by this paper
• High dose therapy and autologous stem cell transplant in older adults with multiple myeloma

  2015cited by this paper
• Autologous Transplantation for Multiple Myeloma in the Era of New Drugs: A Phase III Study of the Intergroupe Francophone Du Myelome (IFM/DFCI 2009 Trial)

  2015cited by this paper
• Long-Term Ixazomib Maintenance Is Tolerable and Improves Depth of Response Following Ixazomib-Lenalidomide-Dexamethasone Induction in Patients (Pts) with Previously Untreated Multiple Myeloma (MM): Phase 2 Study Results

  2014cited by this paper
• Autologous transplantation and maintenance therapy in multiple myeloma.

  2014influential reference
• Maintenance therapy for multiple myeloma.

  2014cited by this paper
• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

  2014cited by this paper
• Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115

  2013cited by this paper
• Salvage second hematopoietic cell transplantation in myeloma.

  2013cited by this paper
• Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.

  2013cited by this paper
• Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment

  2013cited by this paper
• Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial.

  2013cited by this paper
• Lenalidomide Maintenance After Stem-Cell Transplantation For Multiple Myeloma: Follow-Up Analysis Of The IFM 2005-02 Trial

  2013cited by this paper
• First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies.

  2012cited by this paper
• Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

  2012cited by this paper
• Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.

  2012influential reference
• Lenalidomide after stem-cell transplantation for multiple myeloma.

  2012cited by this paper
• Doxycycline Used As Post Transplant Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis Undergoing Autologous Stem Cell Transplantation.

  2012cited by this paper
• Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis.

  2012cited by this paper
• Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

  2012cited by this paper
• Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study

  2011cited by this paper
• Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

  2011cited by this paper
• Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study.

  2011cited by this paper
• Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

  2010cited by this paper
• Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

  2010cited by this paper
• Maintenance therapy in multiple myeloma

  2009cited by this paper
• Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis.

  2009cited by this paper
• Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.

  2009cited by this paper
• High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

  2008cited by this paper
• High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

  2008cited by this paper
• A comparison of allografting with autografting for newly diagnosed myeloma.

  2007cited by this paper
• High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

  2007cited by this paper
• Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study.

  2007cited by this paper
• Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma.

  2006cited by this paper
• Prospective comparison of autologous stem cell transplantation followed by a dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple

  2005cited by this paper
• High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

  2003cited by this paper
• Single versus double autologous stem-cell transplantation for multiple myeloma.

  2003cited by this paper
• Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients

  2001cited by this paper
• Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients.

  2000cited by this paper
• Total therapy with tandem transplants for newly diagnosed multiple myeloma.

  1999cited by this paper
• A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma

  1996cited by this paper
• A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

  1996cited by this paper

• Comparing the efficacy of different dexamethasone regimens for maintenance treatment of multiple myeloma in standard-risk patients non-eligible for transplantation

  2022cites this paper
• Newly diagnosed multiple myeloma patients treated with tandem auto‐allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only

  2020cites this paper
• Long-term follow-up of CALGB (Alliance) 100001: Autologous followed by non-myeloablative allogeneic transplant for multiple myeloma.

  2020cites this paper
• CAR T‐Cell Therapy in Hematologic Malignancies: A Voyage in Progress

  2020cites this paper
• B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review

  2019cites this paper
• Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center.

  2019cites this paper
• Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients

  2018cites this paper
• Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation

  2018cites this paper
• Short overview on the current standard of treatment in newly diagnosed multiple myeloma

  2018cites this paper
• Hematopoietic Stem Cell Transplantation in Myeloma in the Era of Novel Agents

  2018cites this paper
• Long-Term Efficacy of Maintenance Therapy for Multiple Myeloma: A Quantitative Synthesis of 22 Randomized Controlled Trials

  2018cites this paper
• Acute Lymphoblastic Leukemia following Lenalidomide Maintenance for Multiple Myeloma: Two Cases with Unexpected Presentation and Good Prognostic Features

  2018cites this paper
• Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents

  2018cites this paper
• Strategie optymalizacji terapii lenalidomidem u chorych na szpiczaka plazmocytowego

  2017cites this paper
• Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

  2017cites this paper
• Strategie optymalizacji terapii lenalidomidem u chorych na szpiczaka plazmocytowego Optimizing strategies lenalidomide therapy in the treatment of multiple myeloma

  2017cites this paper
• Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

  2017cites this paper
• Myeloma: management of the newly diagnosed high-risk patient.

  2016cites this paper